Empyrean Bio Labs

Empyrean Bio Labs

Shop

Tirzepatide

Price range: $55.00 through $115.00

 A dual GIP and GLP-1 receptor agonist with exceptional effects on appetite regulation, satiety, blood-sugar control, insulin sensitivity, and sustained weight reduction. It is prescribed for type 2 diabetes, long-term weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity.

Research Details

Tirzepatide Scientific Research Overview Tirzepatide is a synthetic peptide that acts as an agonist at both glucose-dependent insulinotropic polypeptide and GLP-1 receptors. Its combined receptor activity has been studied in relation to glucose regulation, insulin sensitivity, appetite-related signaling, energy intake, body weight, and cardiometabolic markers. Published Research Findings In the 72-week SURMOUNT-1 trial involving adults with obesity or overweight without diabetes, average body-weight changes were: 15.0% with the 5 mg study dose 19.5% with the 10 mg study dose 20.9% with the 15 mg study dose 3.1% with placebo The research also reported improvements across several measured cardiometabolic markers. A three-year follow-up of participants with obesity and prediabetes found sustained body-weight reductions and a markedly lower rate of progression to type 2 diabetes during the treatment period compared with placebo. In a 2025 head-to-head study involving adults with obesity without diabetes, tirzepatide produced an average 20.2% body-weight reduction at 72 weeks, compared with a smaller average reduction in the semaglutide group at the maximum tolerated study doses. Evidence and Regulatory Context Tirzepatide is an active ingredient in FDA-approved prescription products for defined indications. These approvals apply only to the FDA-reviewed finished products and do not establish the safety, quality, sterility, or effectiveness of research-use tirzepatide material. Research Links SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity Three-Year Tirzepatide Study in Obesity and Prediabetes Tirzepatide Compared with Semaglutide for Obesity FDA Zepbound Prescribing Information FDA Information About Unapproved GLP-1 Products Research Context: Published findings summarized on this page involve controlled studies of the named molecule and, where applicable, regulated pharmaceutical formulations. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.

StorageStorage Information: Store lyophilized research material tightly sealed, dry, and protected from light at -4°F (-20°C) or below for long-term stability. After laboratory preparation, store in small aliquots according to the product and avoid repeated freeze-thaw cycles; allow cold vials to reach room temperature before opening to minimize condensation.
Compliance Notice: For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Products and information are intended for qualified adult researchers only.

Description

Tirzepatide is a dual GIP and GLP-1 receptor agonist that brings together two major metabolic signaling pathways in a single compound. Through these pathways, tirzepatide enhances glucose-dependent insulin release, improves blood-sugar regulation, strengthens satiety signaling, reduces appetite, and helps regulate how the body processes and stores energy. Its dual-receptor design has produced exceptional interest in metabolic-health and weight-management research.

Clinical trials have demonstrated substantial and sustained reductions in body weight alongside improvements in glucose control and numerous cardiometabolic measurements. Prescription tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for long-term weight management in qualifying adults. Zepbound is also prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity, making tirzepatide the first FDA-approved medication for that specific use. Its influence on appetite, body weight, glucose metabolism, insulin sensitivity, and obesity-related health makes tirzepatide one of the most transformative metabolic compounds developed in recent years.

Additional information

Strength

10 mg, 20 mg, 30 mg

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide”

Your email address will not be published. Required fields are marked *